title: [Laser treatment or intravitreal VEGF inhibition for aggressive posterior retinopathy of prematurity?].
abstract: A prematurely born male infant (24+5 gestational weeks, birth weight 485 g) was diagnosed with bilateral aggressive posterior retinopathy of prematurity (AP-ROP) in zone I. After obtaining informed written consent from the parents, one eye was treated with diode laser photocoagulation and the other eye with 0.25 mg intravitreal ranibizumab. Laser photocoagulation was found to be an effective tool for fast regression of AP-ROP; however, medium-term evaluation showed poor macular formation and peripheral retinal detachment. The intravitreal injection led to a slower but better control of the AP-ROP and central foveal reflexes showed better anatomical outcome.
authors.affiliation: Klinik und Poliklinik für Augenheilkunde, Universitätsklinikum Regensburg, Franz-Josef-Strauß-Allee 11, 93053, Regensburg, Deutschland, teresa.barth@klinik.uni-regensburg.de.
authors.forename: T
authors.initials: T
authors.lastname: Barth
authors.forename: K
authors.initials: K
authors.lastname: Hufendiek
authors.forename: H
authors.initials: H
authors.lastname: Helbig
authors.forename: I
authors.initials: I
authors.lastname: Oberacher-Velten
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D003131:Combined Modality Therapy; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D058449:Intravitreal Injections; D017075:Laser Coagulation / Q000379:methods*; D053685:Laser Therapy / Q000379:methods*; D008297:Male; D000069579:Ranibizumab / Q000008:administration & dosage*; D012178:Retinopathy of Prematurity / Q000175:diagnosis* / Q000628:therapy*; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
chemical_list: D020533:Angiogenesis Inhibitors; D042461:Vascular Endothelial Growth Factor A; D000069579:Ranibizumab